Modality
ASO
MOA
BETi
Target
JAK1
Pathway
Angiogenesis
PsA
Development Pipeline
Preclinical
~Dec 2019
→ ~Mar 2021
Phase 1
Jun 2021
→ Apr 2028
Phase 1Current
NCT08142634
761 pts·PsA
2021-06→2028-04·Active
761 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-04-042.0y awayInterim· PsA
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1
Active
Catalysts
Interim
2028-04-04 · 2.0y away
PsA
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08142634 | Phase 1 | PsA | Active | 761 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα |